Access Pharmaceuticals To Host Investor Call On Wednesday, May 23, 2012 - $ACCP

Access Pharmaceuticals To Host Investor Call On Wednesday, May 23, 2012 - $ACCP

Company Schedules Conference Call Wednesday, May 23rd at 11:00AM ET to Update Investors on MuGard Commercial Activities

ACCESS PHARMACEUTICALS, INC. (ACCP.OB), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on MuGardcommercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

The investor conference call is scheduled to be held on Wednesday, May 23, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or             201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on May 23, 2012 at 1:00 pm ET, through June 6, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing             877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access Pharmaceuticals:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. 

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.